NAVEGAL LABORATORIES
Pharmaceutical company · 192 brands · 182 molecules
Ranked #90 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems
Company overview
NAVEGAL LABORATORIES is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 192 product registrations across 182 distinct molecules. It is the 79th largest registrant in Pakistan by product count, and ranks 90th of 213 in Other Beta-Lactam, Cephalosporins & Penems. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Quinolone Antibacterials. It has no DRAP recall, shortage or safety notices on record.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by NAVEGAL
92 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Price band (DRAP official ceilings)
Regulatory record
No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for NAVEGAL
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included